document_id,subject_str,predicate_org,predicate,object_str,text
30160001,a heterogeneous group of carcinomas,has advanced,have advance,in recent years,Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .
30160001,Tumors in the neck region,include,include,a heterogeneous group of carcinomas whose treatment has advanced in recent years,Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .
30160001,Tumors in the head region,include,include,a heterogeneous group of carcinomas whose treatment has advanced in recent years,Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .
30160002,Tumors in the neck region,comprise,comprise,a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years,Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160002,Tumors in the head region,comprise,comprise,a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years,Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160002,carcinomas progress,has been observed,have be observe,in recent years,Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160002,heterogeneous group carcinomas therapy progress,has been observed,have be observe,in recent years,Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
30160021,This shift,changes,change,the understanding of the disease,"This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected ."
30160021,This shift,changes,change,the life expectancy of those,"This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected ."
30160021,This shift,changes,change,its therapy,"This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected ."
30160022,This,changes,change,the understanding of the disease,"This changes the understanding of the disease , its therapy and the life expectancy of those affected ."
30160022,This,changes,change,the life expectancy of those,"This changes the understanding of the disease , its therapy and the life expectancy of those affected ."
30160022,This,changes,change,its therapy,"This changes the understanding of the disease , its therapy and the life expectancy of those affected ."
30160031,This work,focuses,focus,on radiation therapy,"This work focuses on radiation therapy , a treatment option with possible short- and long-term complications , and the resulting consequences for the patients ' quality of life ."
30160031,This work,focuses,focus,on the resulting consequences for the patients ' quality of life,"This work focuses on radiation therapy , a treatment option with possible short- and long-term complications , and the resulting consequences for the patients ' quality of life ."
30160032,The focus here,will be,will be,on radiation treatment,"The focus here will be on radiation treatment , a treatment option with potential short- and long-term complications and the resulting consequences for patients ' quality of life ."
30160041,which supportive measures,can be taken,can be take,after radiation therapy with the help of clinical pharmacists,"Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists ."
30160041,we,show,show,which supportive measures can be taken during radiation therapy with the help of clinical pharmacists,"Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists ."
30160041,we,show,show,which supportive measures can be taken after radiation therapy with the help of clinical pharmacists,"Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists ."
30160041,which supportive measures,can be taken,can be take,during radiation therapy with the help of clinical pharmacists,"Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists ."
30160042,which supportive measures,can be taken,can be take,after radiation treatment with the participation of clinical pharmacists,"Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists ."
30160042,which supportive measures,can be taken,can be take,during radiation treatment with the participation of clinical pharmacists,"Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists ."
30170001,Daunorubicin,has been established,have be establish,as important cornerstone in ALL- and AML-treatment since many years,Daunorubicin has been established as important cornerstone in ALL- and AML-treatment since many years .
30170002,The anthracycline daunorubicin,has been,have be,an integral part of ALL treatment for many years,The anthracycline daunorubicin has been an integral part of ALL and AML treatment for many years .
30170002,The anthracycline daunorubicin,has been,have be,an integral part of AML treatment for many years,The anthracycline daunorubicin has been an integral part of ALL and AML treatment for many years .
30170011,Its metabolite daunorubicinol,does not contribute,doe not contribute,to antineoplastic activities of the anthracycline,"Its metabolite daunorubicinol does not contribute to antineoplastic activities of the anthracycline , however , it may have a potential impact on drug 's cardiotoxicity ."
30170011,it,may have,may have,a potential impact on drug 's cardiotoxicity,"Its metabolite daunorubicinol does not contribute to antineoplastic activities of the anthracycline , however , it may have a potential impact on drug 's cardiotoxicity ."
30170012,The metabolite daunorubicinol,plays,play,less of a role in the antineoplastic effect,"The metabolite daunorubicinol plays less of a role in the antineoplastic effect , but probably more in the potential cardiotoxicity of the cytostatic ."
30170012,The metabolite daunorubicinol,plays,play,more in the potential cardiotoxicity of the cytostatic,"The metabolite daunorubicinol plays less of a role in the antineoplastic effect , but probably more in the potential cardiotoxicity of the cytostatic ."
30170021,Current guidelines in Germany,consider,consider,a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min,"Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other ."
30170021,30 and 50 ml/min,is,be,in contrast to FDA-based guidelines,"Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other ."
30170021,the clinical pharmacokinetic behaviour of doxorubicin,are compared,be compare,with each other,"Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other ."
30170021,the clinical pharmacokinetic behaviour of daunorubicin,are compared,be compare,with each other,"Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other ."
30170021,30 and 50 ml/min,is,be,somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin are compared with each other,"Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other ."
30170022,The currently filed guidelines for dose modification,stipulate,stipulate,that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min,The currently filed guidelines for dose modification stipulate that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min .
30170022,the anthracycline,should only be used,should only be use,at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min,The currently filed guidelines for dose modification stipulate that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min .
30170031,a leukemia patient,may receive,may receive,daunorubicin full dose in the US,"As a consequence , a leukemia patient may receive daunorubicin full dose in the US , and 50 % of curative dose in Germany in case of e.g . GFR 43 ml/min ."
30170031,a leukemia patient,may 50,may 50,% of curative dose in Germany in case of . GFR 43 e.g ml/min,"As a consequence , a leukemia patient may receive daunorubicin full dose in the US , and 50 % of curative dose in Germany in case of e.g . GFR 43 ml/min ."
30170032,the FDA,has not provided,have not provide,a corresponding recommendation to date,"This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin ."
30170032,This requirement,is,be,irritating,"This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin ."
30170032,This requirement,considering,consider,that ( 1 ) the FDA has not provided a corresponding recommendation to date,"This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin ."
30170032,( 2 ) recent work,has identified,have identify,very large clinical pharmacokinetic parallels between daunorubicin,"This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin ."
30170032,( 2 ) recent work,has identified,have identify,very large clinical pharmacokinetic parallels between doxorubicin,"This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin ."
30170041,a revised assessment of current guidelines on a regulatory level,is,be,of great interest for clinical oncologist,"Thus , a revised assessment of current guidelines on a regulatory level is of great interest for clinical oncologist ."
30170042,a leukemia patient with a GFR of 43 ml/min,would receive,would receive,only 50 % of the curatively scheduled dose in Germany compared States,"Thus , a leukemia patient with a GFR of 43 ml/min would receive only 50 % of the curatively scheduled dose in Germany compared with the United States ."
30170052,A timely regulatory reassessment of this issue,is therefore,be therefore,of great clinical oncological interest,A timely regulatory reassessment of this issue is therefore of great clinical oncological interest .
30180001,infections,involving,involve,methicillin-resistant Staphylococcus aureus strains,Vancomycin ( VAN ) is an established treatment option for infections involving methicillin-resistant Staphylococcus aureus strains ( MRSA ) .
30180001,Vancomycin,is,be,an established treatment option for infections,Vancomycin ( VAN ) is an established treatment option for infections involving methicillin-resistant Staphylococcus aureus strains ( MRSA ) .
30180002,Vancomycin,is,be,an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains,Vancomycin ( VAN ) is an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains .
30180011,the target,increased,increase,of VAN plasma through levels,"However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels ."
30180011,. the clinical medical societies the target,ranges,range,of VAN plasma through levels,"However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels ."
30180011,both EUCAST Conversely the clinical medical societies,reduced increased,reduce increase,the `` sensitive '' MIC range to < 2 mg/L the target ranges of VAN plasma,"However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels ."
30180011,the bactericidal effect of VAN on MRSA societies,is reduced,be reduce,( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure VAN plasma through levels,"However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels ."
30180011,the bactericidal effect of VAN on MRSA both,is reduced,be reduce,strains inhibitory ( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure the `` range to < through levels,"However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels ."
30180012,the bactericidal effect of VAN on MRSA,is reduced,be reduce,for strains already,"However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels ."
30180012,the MIC of VAN,increases,increase,to ≥1 mg/l,"However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels ."
30180012,clinical societies,increased,increase,the target ranges for plasma levels,"However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels ."
30180012,CLSI,reduced,reduce,the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l,"However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels ."
30180012,strains the MIC of VAN,increases,increase,to ≥1 mg/l,"However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels ."
30180021,ototoxic effects,limit,limit,the use of increased VAN dosages for the improvement of treatment efficacy,"However , nephrotoxic and ototoxic effects limit the use of increased VAN dosages for the improvement of treatment efficacy ."
30180021,nephrotoxic effects,limit,limit,the use of increased VAN dosages for the improvement of treatment efficacy,"However , nephrotoxic and ototoxic effects limit the use of increased VAN dosages for the improvement of treatment efficacy ."
30180022,ototoxic effects,limit,limit,VAN dose increases to improve therapy,"However , nephro- and ototoxic effects limit VAN dose increases to improve therapy ."
30180022,nephro- effects,limit,limit,VAN dose increases to improve therapy,"However , nephro- and ototoxic effects limit VAN dose increases to improve therapy ."
30180031,Trough level monitoring,are recommended,be recommend,for the optimization of VAN exposure,Trough level monitoring and corresponding dose adjustments are recommended for the optimization of VAN exposure .
30180031,corresponding dose adjustments,are recommended,be recommend,for the optimization of VAN exposure,Trough level monitoring and corresponding dose adjustments are recommended for the optimization of VAN exposure .
30180032,"Valley level measurements after therapy initiation , with dose adjustment if necessary",to optimize,to optimize,VAN exposure,"Valley level measurements after therapy initiation , with dose adjustment if necessary , are recommended to optimize VAN exposure ."
30180032,"Valley level measurements after therapy initiation , with dose adjustment necessary",are recommended,be recommend,to optimize VAN exposure,"Valley level measurements after therapy initiation , with dose adjustment if necessary , are recommended to optimize VAN exposure ."
30180041,the impact of patient characteristics on the attainment of the newly defined target,ranges,range,until day 3,"Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment ."
30180041,we,investigated,investigate,the impact of patient characteristics on the attainment of the newly defined target ranges until day 3,"Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment ."
30180041,the impact of patient characteristics on the attainment of the newly defined target,ranges,range,later in the course of treatment,"Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment ."
30180041,we,investigated,investigate,the impact of patient characteristics on the attainment of the newly defined target ranges,"Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment ."
30180041,the impact of dose regimens on the attainment of the newly defined target,ranges,range,until day 3,"Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment ."
30180042,we,retrospectively examined,retrospectively examine,the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3,"Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later ."
30180042,the influences of patient characteristics on the achievability of newly defined target,ranges,range,for VAN valley levels by therapy day 3,"Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later ."
30180042,we,retrospectively examined,retrospectively examine,the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by,"Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later ."
30180042,we,retrospectively examined,retrospectively examine,the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day later,"Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later ."
30180042,we,retrospectively examined,retrospectively examine,the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by therapy day later,"Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later ."
30180051,dosages,recommended,recommend,by the manufacturers,"With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment ."
30180051,the mean trough levels,remained clearly,remain clearly,below the values,"With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment ."
30180051,the values,recommended,recommend,by current therapeutic guidelines,"With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment ."
30180052,mean valley levels,were,be,significantly below the current guideline recommendation When dosed according to manufacturer 's instructions,"When dosed according to manufacturer 's instructions , mean valley levels were significantly below the current guideline recommendation ( 15-20 mg/l for severe infections ) , particularly in renally healthy patients ."
30180061,only a minority of patients,reached,reach,"plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three Even with body-weight adjusted dosages","Even with body-weight adjusted dosages , only a minority of patients reached plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three ."
30180061,plasma levels,meet,meet,"the guideline recommendations , particularly during the early phase of treatment until day three","Even with body-weight adjusted dosages , only a minority of patients reached plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three ."
30180062,only a minority of patients,achieved,achieve,"valley levels Even with body-weight-based dosing in line with recommendations , especially by therapy day 3","Even with body-weight-based dosing , only a minority of patients achieved valley levels in line with recommendations , especially by therapy day 3 ."
30180071,A moderate correlation,was observed,be observe,between VAN trough levels and body weight-adjusted dosage,A moderate correlation was observed between VAN trough levels and body weight-adjusted dosage .
30180072,a moderate correlation,of,of,valley level with body-weight-based dosing,There was a moderate correlation of valley level with body-weight-based dosing .
30180081,The intraindividual variability of renal function,confounds,confound,the predictability of VAN exposure,The intraindividual variability of renal function which is commonly observed in intensive care patients further confounds the predictability of VAN exposure .
30180081,renal function,is commonly observed,be commonly observe,in intensive care patients,The intraindividual variability of renal function which is commonly observed in intensive care patients further confounds the predictability of VAN exposure .
30180082,more frequent fluctuations in renal function,have,have,unpredictable effects on VAN exposure In ICU patients,"In ICU patients , more frequent fluctuations in renal function have unpredictable effects on VAN exposure ."
30180091,VAN dosages beyond the manufacturer recommendation,are required,be require,to reach the target trough levels In most cases,"In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) ."
30180091,the target trough levels,specified,specify,by the guidelines,"In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) ."
30180091,VAN dosages beyond the manufacturer recommendation,to reach,to reach,the target trough levels specified by the guidelines,"In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) ."
30180092,VAN doses above the manufacturer 's recommendation,are needed,be need,In most cases to achieve the current valley level target of 10 to,"In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients ."
30180092,VAN doses above the manufacturer 's recommendation,are needed achieve,be need achieve,to the current valley level target of to results In most cases,"In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients ."
30180092,doses above current valley level . The results,ranges argue,range argue,"10 to 20 mg/l for early , repeated valley level measurements even in renally healthy patients","In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients ."
30180101,These results,strongly support,strongly support,repeated VAN trough level measurements even in patients with normal renal function,These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .
30180101,early VAN,trough,trough,level measurements even in patients with normal renal function,These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .
30180101,These results,strongly support,strongly support,early VAN trough level measurements in patients with normal function even renal,These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .
30180102,The low exposure in the critical early phase,suggest,suggest,"the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens","The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) ."
30180102,The low exposure in the critical early phase,suggest,suggest,"the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens","The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) ."
30180102,the limited correlation of dosage,suggest,suggest,"the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens","The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) ."
30180102,the limited correlation of exposure,suggest,suggest,"the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens","The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) ."
30180102,the limited correlation of dosage,suggest,suggest,"the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens","The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) ."
30180111,the generally low exposure,observed,observe,in the critical early phase,"Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) ."
30180111,the generally low exposure observed in the critical early phase,suggest,suggest,the use of other antibiotics active against MRSA,"Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) ."
30180111,the generally low exposure observed in the critical early phase,suggest,suggest,the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs,"Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) ."
30180111,the generally low exposure observed in the critical early phase,suggest,suggest,the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues,"Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) ."
30180111,the limited correlation of exposure,suggest,suggest,the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs,"Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) ."
30180121,microbiological responses as well as toxicities,were not investigated,be not investigate,in this study,Clinical and microbiological responses as well as toxicities were not investigated in this study .
30180121,Clinical responses as well as toxicities,were not investigated,be not investigate,in this study,Clinical and microbiological responses as well as toxicities were not investigated in this study .
30190001,ceftazidime,are commonly used,be commonly use,broad spectrum beta-lactam antibiotics in intensive care units,"Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units ."
30190001,Meropenem,are commonly used,be commonly use,broad spectrum beta-lactam antibiotics in intensive care units,"Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units ."
30190001,piperacillin,are commonly used,be commonly use,broad spectrum beta-lactam antibiotics in intensive care units,"Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units ."
30190002,The beta-lactam antibiotics meropenem,are used,be use,in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity,"The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity ."
30190002,The beta-lactam antibiotics ceftazidime,are used,be use,in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity,"The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity ."
30190002,The beta-lactam antibiotics piperacillin,are used,be use,in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity,"The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity ."
30190012,the establishment of therapeutic drug monitoring,is recommended,be recommend,to improve therapeutic outcome,"Due to strong inter- and intraindividual variations in pharmacokinetics , the establishment of therapeutic drug monitoring is recommended to improve therapeutic outcome ."
30190012,the establishment of therapeutic drug monitoring,to improve,to improve,therapeutic outcome,"Due to strong inter- and intraindividual variations in pharmacokinetics , the establishment of therapeutic drug monitoring is recommended to improve therapeutic outcome ."
30190021,an analytical method,measuring,measure,fluctuating serum levels during therapy,Therefore an analytical method was established measuring fluctuating serum levels during therapy .
30190021,an analytical method,was established,be establish,measuring fluctuating serum levels during therapy,Therefore an analytical method was established measuring fluctuating serum levels during therapy .
30190022,an analytical HPLC method,is described,be describe,In the following,"In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably ."
30190031,A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection,was developed,be develope,for simultaneous quantification of these antimicrobial agents,A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190031,A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection,was validated,be validate,for simultaneous quantification of these antimicrobial agents,A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190031,A simple high-performance liquid chromatography ( HPLC ) method with diode array detection,was developed,be develope,for simultaneous quantification of these antimicrobial agents,A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190031,A simple high-performance liquid chromatography ( HPLC ) method with diode array detection,was validated,be validate,for simultaneous quantification of these antimicrobial agents,A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
30190032,The serum levels determined,can be used,can be use,as a valid basis for further therapy decisions then,The serum levels determined can then be used as a valid basis for further therapy decisions .
30190041,a sample amount of 250 µl serum,was spiked,be spike,with cefotaxime as an internal standard For sample preparation,For sample preparation a sample amount of 250 µl serum was spiked with cefotaxime as an internal standard .
30190051,protein,was precipitated,be precipitate,Afterwards,Afterwards protein was precipitated using acetonitrile/methanol ( 1:1 ) .
30190061,The supernatant,was transferred,be transfer,to HPLC,The supernatant was transferred to HPLC .
30190071,A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a pH 2.2 phosphoric acid solution,was used,be use,for separation,A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile and a pH 2.2 phosphoric acid solution was used for separation .
30190071,A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile,was used,be use,for separation,A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile and a pH 2.2 phosphoric acid solution was used for separation .
30190081,Peaks of interest,were detected respectively,be detect respectively,at 240 nm,"Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively ."
30190081,Peaks of interest,were detected respectively,be detect respectively,at 310 nm,"Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively ."
30190081,Peaks of interest,were detected respectively,be detect respectively,at 298 nm,"Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively ."
30190091,The method developed,shows,show,a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml,The method developed shows a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml for each antibiotic in the serum samples .
30190101,the method,to be too,to be too,accurate,Validation has demonstrated the method to be accurate and precise too .
30190101,Validation,has demonstrated,have demonstrate,the method to be accurate too,Validation has demonstrated the method to be accurate and precise too .
30190101,Validation,has demonstrated,have demonstrate,the method to be precise too,Validation has demonstrated the method to be accurate and precise too .
30190101,the method,to be too,to be too,precise,Validation has demonstrated the method to be accurate and precise too .
30190121,The method,is used,be use,in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients currently,The method is currently used in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients .
30200001,The frequency of bacterial infections,is increasing,be increase,worldwide due to the development of antibiotic resistance among pathogens,The frequency of bacterial infections for which antibiotics no longer work is increasing worldwide due to the development of antibiotic resistance among pathogens .
30200002,The frequency of bacterial infections,is increasing,be increase,worldwide due to the development of resistance in pathogens,The frequency of bacterial infections for which antibiotics are no longer effective is increasing worldwide due to the development of resistance in pathogens .
30200002,bacterial infections,are,be,antibiotics no longer effective,The frequency of bacterial infections for which antibiotics are no longer effective is increasing worldwide due to the development of resistance in pathogens .
30200011,"Research topics , in order",include,include,the development of new antibiotics,"Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances ."
30200011,"Research topics , in order",include,include,the finding of resistance-modifying properties of natural substances,"Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances ."
30200011,"Research topics , in order",include,include,the reactivation of existing antibacterial agents,"Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances ."
30200012,research,is being conducted,be be conduct,To counter this threat in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products,"To counter this threat , research is being conducted - in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products ."
30200021,the checkerboard microdilution method,was used,be use,to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae ."
30200021,the checkerboard microdilution method,was used,be use,to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae ."
30200021,the checkerboard microdilution method,to investigate,to investigate,how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens pneumoniae,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae ."
30200021,the checkerboard microdilution method,was used,be use,to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae In the present work,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae ."
30200021,the checkerboard microdilution method,was used,be use,to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens In the present work,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae ."
30200022,the checkerboard microdilution method,was used,be use,"to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work","In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively ."
30200022,the checkerboard microdilution method,was used,be use,to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens In the present work,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively ."
30200022,the checkerboard microdilution method,was used,be use,to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens respectively In the present work,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively ."
30200022,the checkerboard microdilution method,to investigate,to investigate,how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens,"In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively ."
30200022,the checkerboard microdilution method,was used,be use,"to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work","In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively ."
30200031,the essential oils of both plant species,reduce,reduce,the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species,The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031,The results,indicate,indicate,that the essential oils of both plant species reduce the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species,The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031,the essential oils of both plant species,significantly increase,significantly increase,the antibiotic effects,The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031,The results,indicate,indicate,that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species,The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200031,the essential oils of both plant species,reduce,reduce,the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species,The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
30200032,The results,show,show,that the essential oils of both plant species decrease the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species,"The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy ."
30200032,the essential oils of both plant species,decrease,decrease,the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species,"The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy ."
30200032,the essential oils of both plant species,significantly enhancing,significantly enhance,antibiotic efficacy,"The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy ."
30200032,The results,show,show,that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species,"The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy ."
30200032,the essential oils of both plant species,decrease,decrease,the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species,"The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy ."
30200041,The observed potent resistance-modifying properties of the essential oils,favour,favour,further investigations of the phenylpropanoids as the main components of both oils in this context,The observed potent resistance-modifying properties of the essential oils favour further investigations of the phenylpropanoids as the main components of both oils and other natural substances in this context .
30200041,The observed potent resistance-modifying properties of the essential oils,favour,favour,further investigations of the phenylpropanoids as the main components of both other natural substances in this context,The observed potent resistance-modifying properties of the essential oils favour further investigations of the phenylpropanoids as the main components of both oils and other natural substances in this context .
30200042,The potent resistance-modifying properties of the essential oils,suggest,suggest,further investigation of phenylpropanoids as major components of both oils in this context is promising,The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30200042,The potent resistance-modifying properties of the essential oils,suggest,suggest,further investigation of phenylpropanoids as major components of both other natural products in this context is promising,The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30200042,further investigation of phenylpropanoids as major components of both oils in this context,is,be,promising,The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30200042,further investigation of phenylpropanoids as major components of both other natural products in this context,is,be,promising,The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
30210001,substances,are,be,already available,"Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available ."
30210001,researchers,are looking,be look,for effective therapy in substances,"Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available ."
30210001,researchers,are looking,be look,for promising therapy in substances,"Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available ."
30210002,research,is looking,be look,"for promising , effective substances","Since there is still no reliable therapy and not enough approved vaccines against SARS-CoV-2 , research is looking for promising , effective substances that are already available ."
30210002,"promising , effective substances",are,be,already available,"Since there is still no reliable therapy and not enough approved vaccines against SARS-CoV-2 , research is looking for promising , effective substances that are already available ."
30210011,The objective of the current study,is,be,to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2,The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 .
30210011,the herbal preparation,has,have,in vitro antiviral properties,The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 .
30210012,This study,will investigate,will investigate,whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2,"This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses ."
30210012,the herbal preparation,has,have,in vitro antiviral properties against SARS-CoV-2,"This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses ."
30210012,it,to be,to be,antiviral properties against SARS-CoV-2 effective against several other viruses,"This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses ."
30210012,it,has been shown,have be show,effective against other viruses already,"This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses ."
30210021,CPE,to be,to be,effective against several other viruses,CPE has already proved to be effective against several other viruses .
30210021,CPE,has proved,have prove,already,CPE has already proved to be effective against several other viruses .
30210022,the reduction in infection rate,by comparing,by compare,foci-forming units,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units ."
30210022,cell cultures,were infected,be infect,with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units ."
30210022,the reduction in infection rate,was evaluated,be evaluate,by comparing foci-forming units At the Fraunhofer Institute for Immunology,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units ."
30210022,cell cultures,using,use,Cystus Pandalis® extract,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units ."
30210022,cell cultures,were infected,be infect,with SARS-CoV-2 using Cystus Pandalis® At the Fraunhofer Institute for Immunology,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units ."
30210031,cell cultures,treated,treat,with Cystus Pandalis® extract,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units ."
30210031,the reduction in the infection rate,was evaluated,be evaluate,by comparing focus-forming units At the Fraunhofer Institute for Immunology,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units ."
30210031,the reduction in the infection rate,was evaluated,be evaluate,by comparing focus-forming units At the Fraunhofer Institute for Cell Therapy,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units ."
30210031,IZI ) cell cultures treated with Cystus Pandalis® extract,were infected,be infect,with SARS-CoV-2 At the Fraunhofer Institute for Immunology,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units ."
30210031,( IZI ) cell cultures treated with Cystus Pandalis® extract,were infected,be infect,with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy,"At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units ."
30210032,An almost complete reduction in infection rate by CPE,was observed,be observe,at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml,An almost complete reduction in infection rate by CPE was observed at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml .
30210041,An almost complete reduction in the CPE infection rate,was observed,be observe,at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml,An almost complete reduction in the CPE infection rate was observed at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml .
30210042,The mechanism of action of this extract,may be based,may be base,on the high polymer polyphenols,"The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor ."
30210042,the high polymer polyphenols,coat,coat,certain viral epitopes,"The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor ."
30210042,CPE,to act,to act,as an entry inhibitor,"The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor ."
30210042,"the high polymer polyphenols that ,",certain viral epitopes causing,certain viral epitope cause,CPE to act as an entry inhibitor,"The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor ."
30210051,The mechanism of action of this extract,may be based,may be base,on the highly polymeric polyphenols,"The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor ."
30210051,CPE,acts,act,as an entry inhibitor,"The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor ."
30210051,the highly polymeric polyphenols,envelop,envelop,"certain viral epitopes , whereby CPE acts as an entry inhibitor","The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor ."
30210052,it,to use,to use,CPE as prophylaxis against infections with SARS-CoV-2,"Due to the high in vitro activity , it seems reasonable to use CPE as prophylaxis against infections with SARS-CoV-2 ."
30210061,The high in vitro activity of CPE,to make,to make,it a reasonable candidate for prophylaxis against SARS-CoV-2,The high in vitro activity of CPE seems to make it a reasonable candidate for prophylaxis against SARS-CoV-2 .
30220001,Fruits from Apium graveolens,are used traditionally,be use traditionally,in European medicine for the treatment of uncomplicated urinary tract infections,Fruits from Apium graveolens ( celery ) are used traditionally in Persian and European medicine for the treatment of uncomplicated urinary tract infections .
30220001,Fruits from Apium graveolens,are used traditionally,be use traditionally,in Persian medicine for the treatment of uncomplicated urinary tract infections,Fruits from Apium graveolens ( celery ) are used traditionally in Persian and European medicine for the treatment of uncomplicated urinary tract infections .
30220002,The fruits of Apium graveolens L.,are used,be use,in traditional European medicine for the treatment of uncomplicated urinary tract infections,The fruits of Apium graveolens L. ( celery ) are used in traditional Persian and European medicine for the treatment of uncomplicated urinary tract infections ( UTI ) .
30220002,The fruits of Apium graveolens L.,are used,be use,in traditional Persian medicine for the treatment of uncomplicated urinary tract infections,The fruits of Apium graveolens L. ( celery ) are used in traditional Persian and European medicine for the treatment of uncomplicated urinary tract infections ( UTI ) .
30220011,No data,are,be,available on A. graveolens extract on the interplay between uropathogenic E. coli,No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .
30220011,No data,are,be,available on A. graveolens extract on the interplay between the eukaryotic host cells,No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .
30220011,No data,are,be,available on A. graveolens on sensing of the bacteria extract quorum,No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .
30220012,no data,investigating,investigate,the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bacterial quorum sensing,"To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing ."
30220012,no data,investigating,investigate,the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder,"To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing ."
30220012,no data,investigating,investigate,the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from kidney,"To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing ."
30220012,no data,are,be,available investigating influence of corresponding drug extracts with regard To date,"To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing ."
30220012,no data,are,be,available investigating influence of corresponding drug extracts with regard to To date,"To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing ."
30220021,The present study,aimed,aim,to characterize an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays,The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021,The present study,aimed,aim,to characterize an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays,The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021,The present study,aimed to characterize,aim to characterize,an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays,The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021,The present study,aimed to characterize,aim to characterize,an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays,The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220021,The present study,aimed to,aim to,correlate these effects with in vivo data,The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
30220022,A. graveolens,using,use,in vitro studies,The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022,The present studies,describe,describe,a marked anti-adhesive effect of an extract of A. graveolens,The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022,The present studies,describe,describe,a marked anti-quorum sensing effect of an extract of A. graveolens,The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022,A. graveolens,using,use,in vivo studies in the mouse infection model,The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220022,A. graveolens,sensing using,sense use,in vivo studies in the mouse infection model,The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
30220031,"Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits",was characterized,be characterize,by UHPLC/+ESI-QTOF-MS,"Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells ."
30220031,"Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits",was investigated,be investigate,on antiproliferative activity against UPEC,"Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells ."
30220031,"Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits",was investigated,be investigate,on antiproliferative activity against human T24 bladder cells,"Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells ."
30220032,"A hydroalcoholic extract EtOH-water , 1:1 ) of A. graveolens fruit",was phytochemically characterized,be phytochemically characterize,by UHPLC/+ESI-QTOF-MS,"A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells ."
30220032,"extract EtOH-water , 1:1 ) of A. graveolens fruit",was evaluated,be evaluate,for antiproliferative properties against UPEC ( strain,"A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells ."
30220032,extract,"EtOH-water , 1:1 ) of A. graveolens fruit","EtOH - water , 1:1 ) of A. graveolens fruit",was evaluated; for antiproliferative properties against human T24 blast cells,"A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells ."
30220041,Antiadhesive properties of CSE,were investigated,be investigate,within two different in vitro adhesion assays,Antiadhesive properties of CSE were investigated within two different in vitro adhesion assays .
30220042,Anti-adhesive effects of CSE,were tested,be test,by two in vitro adhesion assays,Anti-adhesive effects of CSE were tested by two in vitro adhesion assays .
30220051,BALB/c mice,were used,be use,in an UPEC infection model For in vivo studies,For in vivo studies BALB/c mice were used in an UPEC infection model .
30220052,BALB/c mice,were used,be use,in a UPEC infection model For in vivo studies,"For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively ."
30220052,the effect of CSE on bacterial load in kidney tissues,was investigated,be investigate,in the context of 7-day pretreatment For in vivo studies,"For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively ."
30220052,the effect of CSE on bacterial load in bladder tissues,was investigated respectively,be investigate respectively,in the context of 7-day pretreatment For in vivo studies,"For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively ."
30220052,the effect of CSE on bacterial load in kidney tissues,was investigated respectively,be investigate respectively,in the context of 4- pretreatment For in vivo studies,"For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively ."
30220052,the effect of CSE on bacterial load in bladder tissues,was investigated respectively,be investigate respectively,in the context of 4- pretreatment For in vivo studies,"For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively ."
30220061,The effect of CSE on bacterial load in bladder tissue,was monitored,be monitor,within a 4- days pretreatment,"The effect of CSE on bacterial load in bladder tissue was monitored within a 4- and 7 days pretreatment ( 200 , 500 mg/kg ) of the animals ."
30220061,The effect of CSE on bacterial load in bladder tissue,was monitored,be monitor,within a 7 days pretreatment the,"The effect of CSE on bacterial load in bladder tissue was monitored within a 4- and 7 days pretreatment ( 200 , 500 mg/kg ) of the animals ."
30220062,CSE,is phytochemically characterized,be phytochemically characterize,by the presence of luteolin glycosides,"CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins ."
30220062,CSE,is phytochemically characterized,be phytochemically characterize,by the presence of similar flavones,"CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins ."
30220062,CSE,is phytochemically characterized,be phytochemically characterize,by the presence of furanocoumarins,"CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins ."
30220071,CSE,was dominated,be dominate,by the presence of luteolin-glycosides besides furocoumarins,CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .
30220071,CSE,was dominated,be dominate,by the presence of related flavones besides furocoumarins,CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .
30220072,CSE,exhibits,exhibit,concentration-dependent antiadhesive effects against UPEC strain,"CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 ."
30220072,CSE,shows,show,no cytotoxic effects against UPEC,"CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 ."
30220072,CSE,shows,show,no cytotoxic effects against blast cells,"CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 ."
30220072,CSE,exhibits,exhibit,concentration-dependent antiadhesive effects against UTI89,"CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 ."
30220081,CSE,had,have,no cytotoxic effects against UPEC,CSE had no cytotoxic effects against UPEC and bladder cells .
30220081,CSE,had,have,no cytotoxic effects against bladder cells,CSE had no cytotoxic effects against UPEC and bladder cells .
30220082,CSE,inhibits,inhibit,bacterial quorum sensing in a concentration-dependent manner,CSE inhibits bacterial quorum sensing in a concentration-dependent manner .
30220091,CSE,exerts,exert,a dose dependent antiadhesive activity against UPEC,CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .
30220091,a dose dependent antiadhesive activity against UPEC,strains,strain,NU14,CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .
30220091,a dose dependent antiadhesive activity against UPEC,strains,strain,UTI89,CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .
30220092,7 day pretreatment of mice with CSE,followed,follow,by transurethal UPEC NU14 infection,In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220092,4 day pretreatment of mice with CSE,followed,follow,by transurethal UPEC NU14 infection,In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220092,In vivo 4 day pretreatment of mice with CSE,significantly inhibited,significantly inhibit,bacterial load in bladder tissue,In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220092,In vivo 7 day pretreatment of mice with CSE,significantly inhibited,significantly inhibit,bacterial load in bladder tissue,In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
30220101,CSE,inhibited,inhibit,in a concentration-dependent manner,CSE inhibited in a concentration-dependent manner bacterial quorum sensing .
30220111,CSE,transurethrally infected,transurethrally infect,with UPEC NU14,"4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue ."
30220111,7-day pretreatment of animals with CSE,significantly reduced,significantly reduce,the bacterial load in bladder tissue,"4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue ."
30220111,4- pretreatment of animals with CSE,significantly reduced,significantly reduce,the bacterial load in bladder tissue,"4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue ."
30220121,an antiadhesive extract,is justified,be justify,the traditional use in phytotherapy for UTI,CSE is assessed as an antiadhesive extract for which the traditional use in phytotherapy for UTI is justified .
30220121,CSE,is assessed,be assess,as an antiadhesive extract,CSE is assessed as an antiadhesive extract for which the traditional use in phytotherapy for UTI is justified .
30230001,2- ( 4-Chlorophenyl ) -4-metathiazanone,is,be,the intermediate product for the two step-synthesis of chlormezanone (,"2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate product for the two step-synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant ."
30230002,2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2,is,be,the intermediate in the two-step synthesis of chlormezanone (,"2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate in the two-step synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant ."
30230011,The second step,includes,include,the oxidation of its sulfur atom,The second step includes the oxidation of its sulfur atom .
30230012,The second step,is,be,the oxidation of the sulfur atom,The second step is the oxidation of the sulfur atom .
30230021,the subsequent addition of β-mercaptopropionic acid,leads,lead,to a remarkable better yield,It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
30230021,methylamine,forming,form,the hemiaminale,It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
30230021,the foregoing reaction of 4-chlorobenzaldehyde with methylamine,leads,lead,to a remarkable better yield,It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
30230031,the route via ( 42 % of th . ) .2,could be oxidized,can be oxidize,with sodium perborate superior to potassium permanganate hemimercaptale,than the route via the hemimercaptale ( 42 % of th . ) .2 could be oxidized with sodium perborate superior to potassium permanganate .
30230032,methylamine,reacts,react,with β-mercaptopropionic acid then,"of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) ."
30230032,4-chlorobenzaldehyde,reacts,react,with β-mercaptopropionic acid then,"of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) ."
30230032,the reverse,is added,be add,via the half-mercaptal d.th,"of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) ."
30230032,the half-aminal,is formed,be form,from 4-chlorobenzaldehyde first,"of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) ."
30230041,The racemic chlormezanone,is resolved quickly,be resolve quickly,on a gram scale by preparative column chromatography on a Chiralcel® OD column,"The racemic chlormezanone ( 1 ) is resolved quickly on a gram scale by preparative column chromatography on a Chiralcel® OD column ( tris ( 3,5-dimethyl-phenyl-carbamoyl ) cellulose on silicagel ) ."
30230042,Sodium perborate,is,be,clearly superior to potassium permanganate as an oxidizing agent,Sodium perborate is clearly superior to potassium permanganate as an oxidizing agent .
30230042,Sodium perborate,to,to,potassium permanganate as an oxidizing agent,Sodium perborate is clearly superior to potassium permanganate as an oxidizing agent .
30230051,The resolution,needed,need,only 40 min,"The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column ."
30230051,flow rate,are determined,be determine,prior with an analytical column,"The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column ."
30230051,temperature as the most important factors,are determined,be determine,prior with an analytical column,"The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column ."
30230051,composition of the mobile phase,are determined,be determine,prior with an analytical column,"The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column ."
30230052,The racemic chloromezanone,can be separated rapidly,can be separate rapidly,in the grammaÞstab on a Chiralcel® column,The racemic chloromezanone ( 1 ) can be separated rapidly in the grammaÞstab on a Chiralcel® OD column .
30230061,Both dissociation constants,could be determined,can be determine,for the first time with the aid of a log pKa-Titrator of the Sirius Co.,"Both dissociation constants could be determined for the first time with the aid of a log pKa-Titrator of the Sirius Co. , which needs for the registration of the curves only 15–17 min in the pH range of 2–12 ."
30230061,the Sirius Co.,needs,need,for the registration of the curves only,"Both dissociation constants could be determined for the first time with the aid of a log pKa-Titrator of the Sirius Co. , which needs for the registration of the curves only 15–17 min in the pH range of 2–12 ."
30230062,the separation,requires,require,only 40 min then,"If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min ."
30230062,the crucial factors such as flow rate,are determined,be determine,on analytical columns first,"If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min ."
30230062,the crucial factors such as temperature,are determined,be determine,on analytical columns first,"If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min ."
30230062,the crucial factors such as mobile phase composition,are determined,be determine,on analytical columns first,"If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min ."
30230071,This speed,outplayed,outplay,the disturbing cleavage of the S-C bond of chlormezanone at strong acidic pH values,This speed outplayed the disturbing cleavage of the S-C bond of chlormezanone at strong acidic and alkaline pH values .
30230071,This speed,outplayed,outplay,the disturbing cleavage of the S-C bond of chlormezanone at strong alkaline pH values,This speed outplayed the disturbing cleavage of the S-C bond of chlormezanone at strong acidic and alkaline pH values .
30230072,the log pKa titrator from Sirius Co.,requires,require,only 15-17 min to register the titration curves in the pH range 2-12,"For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 ."
30230072,the two dissociation constants of 1,could be determined,can be determine,For the first time,"For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 ."
30230072,only 15-17 min,to register,to register,the titration curves in the pH range 2-12,"For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 ."
30230082,This speed,glosses,gloss,over the interfering break in the S-C bond of 1 in the strongly acidic pH ranges,This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .
30240001,an antiseptic wound powder,based,base,on the antibiotic tyrothricin,"Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions ."
30240001,The tolerance of an antiseptic wound powder,was investigated,be investigate,"in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions","Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions ."
30240001,The efficacy of an antiseptic wound powder,was investigated,be investigate,"in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions","Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions ."
30240001,The tolerance of an antiseptic wound powder,was investigated,be investigate,"in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions","Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions ."
30240001,The efficacy of an antiseptic wound powder,was investigated,be investigate,"in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions","Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions ."
30240002,an antibiotic wound powder,containing,contain,the active ingredient tyrothricin,"Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions ."
30240002,the tolerability of an antibiotic wound powder,were investigated,be investigate,"in posttraumatic skin lesions In a prospective , randomized multicenter study","Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions ."
30240002,the tolerability of an antibiotic wound powder,were investigated,be investigate,"in postoperative skin lesions In a prospective , randomized multicenter study","Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions ."
30240002,the efficacy of an antibiotic wound powder,were investigated,be investigate,"in posttraumatic skin lesions In a prospective , randomized multicenter study","Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions ."
30240002,the efficacy of an antibiotic wound powder,were investigated,be investigate,"in postoperative skin lesions In a prospective , randomized multicenter study","Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions ."
30240011,131 male patients from 18–85 years,were included,be include,with posttraumatic cutaneous lesions with infection In 5 centers,"Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) ."
30240011,131 male patients from 18–85 years,were included,be include,with posttraumatic cutaneous lesions in danger of infection In 5 centers,"Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) ."
30240011,131 female patients from 18–85 years,were included,be include,with posttraumatic cutaneous lesions with infection In 5 centers,"Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) ."
30240011,131 female patients from 18–85 years,were included,be include,with posttraumatic cutaneous lesions in danger of infection In 5 centers,"Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) ."
30240011,131 male patients from 18–85 years,were included,be include,with surgical cutaneous lesions in danger of infection In 5 centers,"Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) ."
30240012,131 men aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 ),participated,participate,In 5 study sites,"PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated ."
30240012,131 men aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ),participated,participate,In 5 study sites,"PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated ."
30240012,131 women aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 ),participated,participate,In 5 study sites,"PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated ."
30240012,131 women aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ),participated,participate,In 5 study sites,"PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated ."
30240012,131 men,aged,age,18 to 85 years with a infection-prone skin lesion,"PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated ."
30240021,tyrothricin 0.1 g tyrothricin per 100 g of vehicle,was applied,be apply,to the wound In a double-blind study twice daily for 9 days,"In a double-blind study , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g of vehicle ) or placebo powder ( n = 69 ) was applied to the wound twice daily for 9 days ."
30240021,placebo powder,was applied,be apply,to the wound In a double-blind study twice daily for 9 days,"In a double-blind study , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g of vehicle ) or placebo powder ( n = 69 ) was applied to the wound twice daily for 9 days ."
30240022,placebo powder,was,be,to be applied to the wound area 2 × daily During 9 days of double-blind treatment,"During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily ."
30240022,tyrothricin 0.1 g tyrothricin per 100 g base,was,be,to be applied to the wound area 2 × daily During 9 days of double-blind treatment,"During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily ."
30240022,tyrothricin 0.1 g tyrothricin per 100 g base,to be applied,to be apply,to the wound area 2 daily,"During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily ."
30240022,placebo powder,to be applied ×,to be apply ×,to the wound area 2 daily,"During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily ."
30240031,The primary aim,was,be,to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment (,The primary aim was to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment ( α = 0.025 ; one-sided ) .
30240032,The primary efficacy parameter,was,be,the average daily reduction in wound radius,The primary efficacy parameter was the average daily reduction in wound radius calculated from wound area between the start and end of randomized treatment ( α = 0.025 ; unilateral ) .
30240032,wound radius,calculated,calculate,from wound area between the start and end of randomized treatment ( α = 0.025,The primary efficacy parameter was the average daily reduction in wound radius calculated from wound area between the start and end of randomized treatment ( α = 0.025 ; unilateral ) .
30240041,a wound index,was calculated,be calculate,from the assessments of rubor,"Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment ."
30240041,a wound index,was calculated,be calculate,from the assessments of crusting,"Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment ."
30240041,a wound index,was calculated,be calculate,from the assessments of exudation,"Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment ."
30240041,a wound index,was calculated,be calculate,from the assessments of pain,"Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment ."
30240041,a wound index,was calculated,be calculate,from the assessments of functional impairment,"Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment ."
30240042,A wound index,was calculated,be calculate,from the assessment of symptoms of redness,"A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation ."
30240042,A wound index,was calculated,be calculate,from the assessment of symptoms of coatings,"A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation ."
30240042,A wound index,was calculated,be calculate,from the assessment of symptoms of exudation,"A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation ."
30240042,A wound index,was calculated,be calculate,from the assessment of symptoms of pain,"A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation ."
30240042,A wound index,was calculated,be calculate,from the assessment of symptoms of functional limitation,"A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation ."
30240051,The treatment groups,were,be,comparable at baseline,Results : The treatment groups were comparable at baseline .
30240052,Wound radius,decreased,decrease,by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the collective at comparable baseline intention-to-treat,Results : Wound radius decreased by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the intention-to-treat collective at comparable baseline ( p = 0.016 ; one-sided ) .
30240061,the radius of the lesions,was reduced,be reduce,at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for During randomized treatment,"During randomized treatment , the radius of the lesions was reduced at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for placebo ( p = 0.016 ; one-sided ; intention-to-treat data set ) ."
30240062,The wound index,decreased,decrease,by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo,The wound index decreased by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo ( p = 0.0048 ; one-sided ) .
30240071,The wound index,decreased respectively,decrease respectively,"at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin ,","The wound index decreased at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin and placebo , respectively ( p = 0.0048 ; one-sided ) ."
30240071,The wound index,decreased respectively,decrease respectively,"at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for placebo ,","The wound index decreased at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin and placebo , respectively ( p = 0.0048 ; one-sided ) ."
30240072,a causal relationship with the medication,could not be ruled out,can not be rule out,in only 3 cases under placebo,"Of 4 adverse events in each of the two treatment groups , a causal relationship with the medication could not be ruled out in only 3 cases under placebo ."
30240081,4 adverse events,occurred,occur,in each group,4 adverse events occurred in each group .
30240082,The results,demonstrate,demonstrate,the promotion of healing of infection-prone skin lesions by Tyrothricin powder,Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .
30240082,The results,demonstrate,demonstrate,the promotion of healing of infected skin lesions by Tyrothricin powder,Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .
30240082,The results,demonstrate,demonstrate,its superiority over placebo,Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .
30240091,A causal relationship with the investigational drug,could not be excluded,can not be exclude,in 3 of the placebo group,A causal relationship with the investigational drug could not be excluded in 3 of the placebo group .
30240092,the substance,is,be,suitable for therapy in skin injuries,"Due to the good tolerability and the lack of a systemic effect , the substance is suitable for therapy in skin injuries ."
30240101,The results,confirm,confirm,the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection,Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .
30240101,The results,confirm,confirm,the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of danger of infection,Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .
30240111,A superior efficacy,compared,compare,to placebo,A superior efficacy compared to placebo was demonstrated .
30240121,the absence of a systemic effects tyrothricin powder,is,be,appropriate for the treatment of superficial skin lesions,Due to its good tolerability and the absence of a systemic effects tyrothricin powder is appropriate for the treatment of superficial skin lesions .
30240121,tolerability tyrothricin powder,is,be,appropriate for the treatment of superficial skin lesions,Due to its good tolerability and the absence of a systemic effects tyrothricin powder is appropriate for the treatment of superficial skin lesions .
30250001,"2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine",reacted selectively,react selectively,with aromatic amines by substitution at the 5-position,"2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted with aromatic amines selectively by substitution at the 5-position to yield the amidines 2 ."
30250002,"2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine",reacted selectively,react selectively,with aromatic amines with substitution at the 5-position,"2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted selectively with aromatic amines with substitution at the 5-position to give the amidines 2 ."
30250011,The 4-aminophenol 2c,could also be synthesized,can also be synthesize,by cleavage of the ether 2b,The 4-aminophenol 2c could also be synthesized by cleavage of the ether 2b .
30250012,The 4-aminophenol 2c,could also be prepared,can also be prepare,by ether cleavage of 2b,The 4-aminophenol 2c could also be prepared by ether cleavage of 2b .
30250021,The structure of 2c,was proved,be prove,by X-ray crystal analysis,The structure of 2c was proved by X-ray crystal analysis .
30250031,Aminomethylation of 2c,yielded,yield,the amodiaquine analogue 3,Aminomethylation of 2c yielded the amodiaquine analogue 3 .
30250032,Aminomethylation of 2c,afforded,afford,the amodiaquine analogue 3,Aminomethylation of 2c afforded the amodiaquine analogue 3 .
30250041,The mono- derivatives 4,were obtained,be obtain,by reaction of compound 1 with phenol Mannich base hydrochlorides,The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250041,The bisaminomethylated derivatives 4,were obtained,be obtain,by reaction of compound 1 with phenol Mannich base hydrochlorides,The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250041,The bisaminomethylated derivatives 5,were obtained,be obtain,by reaction of compound 1 with phenol Mannich base hydrochlorides,The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250041,The mono- derivatives 5,were obtained,be obtain,by reaction of compound 1 with phenol Mannich base hydrochlorides,The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
30250042,Reaction of 1 with phenol Mannich base hydrochlorides,gave,give,the bisaminomethylated derivatives 4,Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250042,Reaction of 1 with phenol Mannich base hydrochlorides,gave,give,the mono- derivatives 4,Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250042,Reaction of 1 with phenol Mannich base hydrochlorides,gave,give,the bisaminomethylated derivatives 5,Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250042,Reaction of 1 with phenol Mannich base hydrochlorides,gave,give,the mono- derivatives 5,Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
30250051,Compounds 3–5,were tested,be test,in vitro for antimalarial activity,Compounds 3–5 were tested in vitro for antimalarial activity using chloroquine-sensitive and resistant Plasmodium-falciparum strains .
30250052,Compounds 3-5,were tested,be test,for activity against malaria with a chloroquine-sensitive Plasmodium falciparum strain in vitro,Compounds 3-5 were tested for activity against malaria with a chloroquine-sensitive and -resistant Plasmodium falciparum strain in vitro .
30250052,Compounds 3-5,were tested,be test,for activity against malaria with a -resistant Plasmodium falciparum strain in vitro,Compounds 3-5 were tested for activity against malaria with a chloroquine-sensitive and -resistant Plasmodium falciparum strain in vitro .
30250061,The highest activities,were shown,be show,by the pyronaridine-type compounds 5a with IC50,The highest activities were shown by the pyronaridine-type compounds 5a and 5b with IC50 values of approximately 200 nM .
30250061,The highest activities,were shown,be show,by the pyronaridine-type compounds 5b IC50,The highest activities were shown by the pyronaridine-type compounds 5a and 5b with IC50 values of approximately 200 nM .
30250062,Pyronaridine analogues 5a,showed,show,the best activities with IC50 values around 200 nM,Pyronaridine analogues 5a and 5b showed the best activities with IC50 values around 200 nM .
30250062,Pyronaridine analogues 5b,showed,show,the best activities with IC50 values around 200 nM,Pyronaridine analogues 5a and 5b showed the best activities with IC50 values around 200 nM .
